Are you a Veteran of the United States Armed Forces?

Please complete a short survey about prostate cancer care for Veterans to help us learn what's working well and what needs improvement in the care Veterans receive.

Veterans prostate cancer care survey Complete the Survey
ZERO Summit 2021 banner

Understanding Today's Treatment Challenges

Two representatives of Erleada at a tabling event

Erleada, also known as apalutamide, is an androgen receptor inhibitor that was approved by the FDA for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). Chelsie Ferrell, a physician assistant at Advanced Urology Institute, talks about Erleada as a prostate cancer treatment option, as well as its possible side effects and how to manage them.

This session was part of our VIRTUAL ZERO Prostate Cancer Summit, a free online event that took place from February 28 to March 4, 2021.


Watch

Contributor

Shelby Moneer Headshot
Shelby Moneer, Vice President, Patient Programs & Education

Shelby Moneer was the Vice President of Patient Programs & Education at ZERO Prostate Cancer until April 2025.

Share